Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
David R LallyAnat LoewensteinJennifer J ArnoldYit C YangKinfemichael GedifCatherine BestHersh PatelRamin TadayoniJeffrey S HeierPublished in: Eye (London, England) (2022)
In this analysis, anatomical and visual outcomes were better with brolucizumab compared with aflibercept. Brolucizumab may therefore achieve greater disease control than aflibercept in nAMD patients with early persistent retinal fluid.